SpectraCure AB (publ) (SPEC.ST)
SEK 1.7
(-2.41%)
SEK 1.7
(-2.41%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 4.39 Million SEK | 1528.52% |
| 2022 | 270 Thousand SEK | -89.15% |
| 2021 | 2.48 Million SEK | -28.04% |
| 2020 | 3.45 Million SEK | -28.8% |
| 2019 | 4.85 Million SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 4.06 Million SEK | 0.0% |
| 2024 Q2 | 3.64 Million SEK | 0.0% |
| 2023 Q1 | - SEK | -100.0% |
| 2023 FY | 4.39 Million SEK | 1528.52% |
| 2023 Q4 | 4.39 Million SEK | -9.81% |
| 2023 Q3 | 4.87 Million SEK | -15.93% |
| 2023 Q2 | 5.79 Million SEK | 0.0% |
| 2022 Q1 | 2.01 Million SEK | -18.92% |
| 2022 FY | 270 Thousand SEK | -89.15% |
| 2022 Q4 | 270 Thousand SEK | -68.6% |
| 2022 Q3 | 860 Thousand SEK | -40.32% |
| 2022 Q2 | 1.44 Million SEK | -28.59% |
| 2021 FY | 2.48 Million SEK | -28.04% |
| 2021 Q1 | 3.12 Million SEK | -9.66% |
| 2021 Q2 | 3.4 Million SEK | 9.02% |
| 2021 Q3 | 3.04 Million SEK | -10.74% |
| 2021 Q4 | 2.48 Million SEK | -18.15% |
| 2020 Q1 | 4.56 Million SEK | -5.97% |
| 2020 Q2 | 4.16 Million SEK | -8.84% |
| 2020 Q3 | 3.75 Million SEK | -9.82% |
| 2020 Q4 | 3.45 Million SEK | -7.88% |
| 2020 FY | 3.45 Million SEK | -28.8% |
| 2019 Q2 | 6.96 Million SEK | 3280.58% |
| 2019 Q1 | 206 Thousand SEK | 0.0% |
| 2019 FY | 4.85 Million SEK | 0.0% |
| 2019 Q4 | 4.85 Million SEK | -25.45% |
| 2019 Q3 | 6.51 Million SEK | -6.43% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2014 Q1 | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Acarix AB (publ) | - SEK | -Infinity% |
| ADDvise Group AB (publ) | 1.45 Billion SEK | 99.698% |
| ADDvise Group AB (publ) | 1.45 Billion SEK | 99.698% |
| Arcoma AB | 1.92 Million SEK | -128.179% |
| Bactiguard Holding AB (publ) | 42.3 Million SEK | 89.607% |
| BICO Group AB (publ) | 1.75 Billion SEK | 99.75% |
| Boule Diagnostics AB (publ) | 57.7 Million SEK | 92.38% |
| CellaVision AB (publ) | 28.66 Million SEK | 84.66% |
| Clinical Laserthermia Systems AB (publ) | 223 Thousand SEK | -1871.749% |
| Chordate Medical Holding AB (publ) | - SEK | -Infinity% |
| C-Rad AB (publ) | 1.75 Million SEK | -150.827% |
| Duearity AB (publ) | 2.94 Million SEK | -49.558% |
| Dignitana AB (publ) | 6.07 Million SEK | 27.645% |
| Episurf Medical AB (publ) | 2.3 Million SEK | -91.174% |
| Getinge AB (publ) | 3.9 Billion SEK | 99.887% |
| Scandinavian Real Heart AB (Publ) | 6.35 Million SEK | 30.788% |
| Iconovo AB (publ) | 4.9 Million SEK | 10.391% |
| Integrum AB (publ) | 4.84 Million SEK | 9.238% |
| Luxbright AB (publ) | 206.02 Thousand SEK | -2034.217% |
| Mentice AB (publ) | 2.14 Million SEK | -105.084% |
| OssDsign AB (publ) | 214 Thousand SEK | -1954.673% |
| Paxman AB (publ) | 2.53 Million SEK | -73.657% |
| Promimic AB (publ) | - SEK | -Infinity% |
| Qlife Holding AB (publ) | 3 Million SEK | -46.372% |
| SciBase Holding AB (publ) | 4.17 Million SEK | -5.217% |
| ScandiDos AB (publ) | - SEK | -Infinity% |
| Sectra AB (publ) | 19.2 Million SEK | 77.104% |
| Sedana Medical AB (publ) | 1.01 Million SEK | -334.486% |
| Senzime AB (publ) | 8.57 Million SEK | 48.741% |
| Stille AB | 38.06 Million SEK | 88.449% |
| Vitrolife AB (publ) | 1.87 Billion SEK | 99.765% |
| Xvivo Perfusion AB (publ) | 21.16 Million SEK | 79.229% |